NuCana (NASDAQ:NCNA) Trading Down 0.5% – Here’s Why

NuCana PLC Sponsored ADR (NASDAQ:NCNA) fell 0.5% during trading on Thursday . The company traded as low as $2.01 and last traded at $2.02. 41,854 shares were traded during trading, a decline of 3% from the average session volume of 43,071 shares. The stock had previously closed at $2.03.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

NuCana Stock Down 0.5%

The business’s 50 day moving average is $1.99 and its 200-day moving average is $2.61. The firm has a market cap of $8.40 million, a P/E ratio of -0.68 and a beta of 2.18.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.64) by $1.39.

Institutional Trading of NuCana

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC increased its stake in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,000 shares of the company’s stock after buying an additional 6,774 shares during the period. FNY Investment Advisers LLC owned about 33.33% of NuCana worth $36,000 at the end of the most recent reporting period. 44.00% of the stock is currently owned by institutional investors.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.